@article {Chiesa2020.09.30.20204479, author = {Scott T. Chiesa and Marietta Charakida and Georgios Georgiopoulos and Justin D. Roberts and Simon J. Stafford and Chloe Park and Juha Mykk{\"a}nen and Mika K{\"a}h{\"o}nen and Terho Lehtim{\"a}ki and Mika Ala-Korpela and Olli Raitakari and Alun D. Hughes and Naveed Sattar and Nicholas J. Timpson and John E. Deanfield}, title = {Elevated glycoprotein acetyl levels in adolescence and early adulthood predict adverse cardiometabolic profiles and risk of metabolic syndrome in up to 10 year follow-up}, elocation-id = {2020.09.30.20204479}, year = {2020}, doi = {10.1101/2020.09.30.20204479}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective Low-grade inflammation in the young may contribute to the early development of adverse cardiometabolic risk profiles. We assessed whether measures of glycoprotein acetylation (GlycA) were better able to detect the development of these changes compared to the more commonly used biomarker high-sensitivity C-reactive protein (CRP), and investigated whether these relationships differed in an adolescent compared to young adult cohort.Research Design and Methods A total of 3306 adolescents (Avon Longitudinal Study of Parents and Children - ALSPAC; mean age 15.4{\textpm}0.3; n=1750) and young adults (Cardiovascular Risk in Young Finns Study - YFS; mean age 32.1{\textpm}5.0; n=1556) were included. Inflammatory biomarkers (GlycA/CRP), body composition (BMI / waist circumference) and cardiometabolic risk factors (blood pressure, triglycerides, HDL-c, glucose, insulin, and homeostasis model of insulin resistance [HOMA_IR]), were measured at baseline and again in 9-10 year follow-up. Metabolic Syndrome (MetS) was defined using adolescent-specific National Cholesterol Education Programme (NCEP) guidelines in ALSPAC and standard NCEP guidelines in YFS.Results GlycA levels showed greater within-subject correlation over the 9-10 year duration of follow-up in both cohorts when compared to CRP, particularly in the younger adolescent group. In adjusted models, only GlycA was found to increase in line with cardiometabolic risk factor burden at baseline, and to predict adverse changes in several cardiometabolic risk factors in follow-up. In both cohorts, GlycA predicted future risk of MetS (OR [95\%CI] for Q4 vs. Q1 = 1.95 [1.08,3.53] and 2.74 [1.30,5.73] for ALSPAC and YFS, respectively), whereas CRP showed a neutral or even negative relationship in fully-adjusted models (OR [95\%CI] = 0.50 [0.29,0.86] and 0.93 [0.53,1.64]).Conclusions Chronic inflammation is associated with adverse cardiometabolic risk profiles from as early as adolescence and predicts risk of future cardiometabolic risk and MetS in up to 10 year follow-up. GlycA may be a more sensitive inflammatory biomarker to CRP for detecting early cardiometabolic and cardiovascular risk in the young.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and STC will serve as guarantor for the contents of this paper. This research was specifically funded through grants from the British Heart Foundation (PG/18/45/33814; CS/15/6/31468), Wellcome Trust and MRC (076467/Z/05/Z), and NIH (R01 DK077659). The Young Finns Study has been financially supported by the Academy of Finland: grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation and the Finnish Society of Clinical Chemistry. MAK has a research grant from the Sigrid Juselius Foundation, Finland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In ALSPAC, ethical approval was obtained from the ALSPAC Ethics and Law Committee and Local Research Ethics Committees. In YFS, written informed consent was obtained from local research ethics committees. All ethical approvals from both cohorts conformed to the Declaration of Helsinki and all biological samples used in the study were collected in accordance with the Human Tissue Act (2004).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/09/30/2020.09.30.20204479}, eprint = {https://www.medrxiv.org/content/early/2020/09/30/2020.09.30.20204479.full.pdf}, journal = {medRxiv} }